Physician profile
Ronald Hinebaugh
NPI 1720401359
$198.99
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $12.63 · 2022: $25.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $32.35 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $28.25 | 2019 | |
| Incyte Corporation | $25.62 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.38 | 2019 | |
| Emmaus Medical, INC. | $17.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.61 | 2019 | |
| Dova Pharmaceuticals | $16.53 | 2019 | |
| Astellas Pharma US INC | $14.63 | 2019 | |
| Eusa Pharma (US) LLC | $13.62 | 2019 | |
| Puma Biotechnology, INC. | $12.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hinebaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.